免疫檢查點抑制劑在癌症治療的發展與應用

Application of Immune Checkpoint Inhibitor in Cancer Treatment

10.3966/168395442018061801002

黃國埕(Kuo-Cheng Huang)

腫瘤護理雜誌

18卷1期（2018 / 06 / 01）

13 - 27

繁體中文

近幾年來蓬勃發展的免疫治療，為人類抗癌的戰爭帶來了一個嶄新的契機，其中免疫檢查點抑制劑已在多個臨床試驗中被證明它對不同癌症，包括非小細胞肺癌、大腸直腸癌、腎臟及泌尿道癌、頭頸癌、黑色素癌、胃癌、肝細胞癌和淋巴癌等的療效。目前的免疫檢查點抑制劑（immune checkpoint inhibitor），主要作用在CTLA-4和PD-1這兩個受體及PD-L1配體上，藉由恢復T細胞的活化，以加強人體對抗腫瘤的免疫反應，以達到腫瘤治療效果。相較於傳統的化學治療，免疫療法的副作用較為輕微。但是當病人免疫力被加強後，如果去傷害自身的組織器官，會造成類似自體免疫疾病的臨床表徵，產生所謂免疫治療的相關副作用。此類副作用可能影響人類所有器官，其中又以腸胃道、內分泌腺體、皮膚及肝臟發生率為最高。在治療期間甚至治療停止後，需持續監控病人異常的症狀，嚴重副作用發生時，可能會需要停止免疫治療用藥，同時併用全身性的類固醇治療。由於免疫治療費用昂貴，且非每位病人皆會有療效，故未來很重要的工作便是找出適當的預測因子，篩選適合的病人接受治療。而將來免疫治療能否取代現行的標準治療，治療的先後順序或能否協同治療以達最大治療效果，則有賴更多的臨床試驗來回答這些問題。

The rapid development of immunotherapy in recent years has brought new hope for human beings in defeating the cancer. Among the various immunotherapy agents, immune checkpoint inhibitors have demonstrated their effectiveness in treating different types of metastatic cancer such as non-small cell lung cancer, colorectal cancer, renal cell and genitourinary cancer, head and neck cancer, malignant melanoma, etc. Immune checkpoint inhibitors activate the function of T-cells by targeting CTLA-4 and PD-1 receptors and ligand PD-L1, thereby, enhancing human immune response to kill cancer cells. In comparison with chemotherapy, the side effects of immunotherapy may be minor. Nonetheless, activation of immune system can result in self-attack on normal organs which leads to a wide range of systemic symptoms and signs, the so-called immune-related adverse events. Gastrointestinal tract, endocrine system, skin and liver are particularly the most commonly involved sites. It is crucial to closely monitor patients' responses and abnormal symptoms. Steroid therapy or discontinuation of immunotherapy may be considered when needed. It should be noted that not every patient responds to immunotherapy, and added to that the high cost of this novelty therapy, it is imperative to identify a reliable predictor to help determine which patient can get clinical benefit from the therapy. Further clinical trials are needed to establish better integration of immunotherapy into current standard treatment.

1. Atkins, MB,Plimack, ER,Puzanov, I(2016).Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results.Ann Oncol,6,266-773PD.
2. Balar, AV,Castellano, D,O’Donnell, PH(2017).First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEY-NOTE-052): a multicentre, single-arm, phase 2 study.Lancet Oncol,18,1483.
3. Balar, AV,Galsky, MD,Rosenberg, JE(2017).Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial.Lancet,389,67.
4. Bauml, J,Seiwert, TY,Pfister, DG(2017).Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: Results From a Single-Arm, Phase II Study.J Clin Oncol,35,1542.
5. Bellmunt, J,de Wit, R,Vaughn, DJ(2017).Pembrolizumab as second-line therapy for advanced urothelial carcinoma.N Engl J Med,376,1015.
6. Bendell, JC,Kim, TW,Goh, BC(2016).Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC) (abstract).J Clin oncol,34(15 suppl),3502.
7. Borghaei, H,Paz-Ares, L,Horn, L(2015).Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.New Engl J Med,373,1627-1639.
8. Brahmer, J,Reckamp, KL,Baas, P(2015).Nivolumab versus docetaxel in advanced squamous cell non-small-cell lung cancer.N Engl J Med,373,123-135.
9. Chen, R,Zinzani, PL,Fanale, MA(2017).Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma.J Clin Oncol,35,2125.
10. Chow, LQ,Haddad, R,Gupta, S(2016).Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort.J Clin Oncol
11. Cohen, E,Harrington, K,Le Tourneau, C(2017).Pembrolizumab versus standard of care for recurrent or metastatic head and neck squamous cell carcinoma: phase 3 KEYNOTE-040 trial (abstract LBA45_PR).2017 European Society for Medical Oncology meeting
12. Crocenzi, TS,El-Khoueiry, AB,Cheung, T(2017).Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study (abstract).J Clin Oncol,35(suppl),4013.
13. El-Khoueiry, AB,Sangro, B,Yau, T(2017).Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.Lancet
14. Escudier, B,Motzer, RJ,Sharma, P(2017).Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in checkmate 025.Eur Urol,72-368.
15. Fuchs, CS,Doi, T,Jang, RW(2018).Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 Clinical KEYNOTE-059 Trial.JAMA Oncol
16. Hamid, O,Puzanov, I,Dummer, R(2017).Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemo-therapy for ipilimumab-refractory advanced melanoma.Eur J Cancer,86,37.
17. Harrington, KJ,Ferris, RL,Blumenschein, G, Jr(2017).Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): Health-related quality-of-life results from a randomised, phase 3 trial.Lancet Oncol,18,1104.
18. Herbst, RS,Baas, P,Kim, DW(2015).Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial.Lancet,387,1540-1550.
19. Hodi, FS,Hwu, WJ,Kefford, R(2016).Evaluation of immune related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab.J Clin Oncol,34,1510-1517.
20. Hodi, FS,O’Day, SJ,McDermott, DF(2010).Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med,363,711.
21. Janjigian, YY,Ott, PA,Calvo, E(2017).Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study (abstract).J Clin Oncol,35(suppl),4014.
22. Kang, YK,Boku, N,Satoh, T(2017).Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet,390,2461.
23. Larkin, J,Chiarion-Sileni, V,Gonzalez, R(2015).Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.N Engl J Med,373,23.
24. Le, DT,Durham, JN,Smith, KN(2017).Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.Science,357,409.
25. Le, DT,Uram, JN,Wang, H(2015).PD-1 blockade in tumors with mismatch-repair deficiency.N Engl J Med,372,2509.
26. Le DT, Uram JN, WWang H, et al. Programmed death-1 blockade in mismatch repair deficient colorectal cancer (abstract). J Clin oncol 34, 2016 (suppl; abstr 103). Abstract available online at http://meetinglibrary.asco.org/content/167415-176 (Accessed on July 26, 2016).
27. Long, GV,Atkinson, V,Ascierto, PA(2016).Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: Results from the phase III CheckMate 066 study.Ann Oncol,27,1940.
28. Maio, M,Grob, JJ,Aamdal, S(2015).Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.J Clin Oncol,33,1191.
29. Michot, JM,Bigenwald, C,Champiat, S(2016).Immune-related adverse events with immune checkpoint blockade: A comprehensive review.Eur J Cancer,54,139-148.
30. Motzer, R,Powles, T,Atkins, M(2018).IM-motion151: A randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma.2018 Genitourinary Cancers Symposium
31. Motzer, RJ,Escudier, B,McDermott, DF(2015).Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.N Engl J Med,373,1803.
32. Motzer, RJ,Tannir, NM,McDermott, DF(2018).Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma.N Engl J Med
33. Ott, PA,Hodi, FS,Robert, C(2013).CTLA-4 and PD-1/PD-L1 blockade: New immunotherapeutic modalities with durable clinical benefit in melanoma patients.Clin Cancer Res,19,5300-5309.
34. Overman, MJ,Kopetz, S,McDermott, RS(2016).Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results (abstract).J Clin Oncol,34(15_suppl),3501.
35. Overman, MJ,Lonardi, S,Wong, KYM(2018).Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-ceficient/microsatellite instability-high metastatic colorectal cancer.J Clin Oncol,36(8),773-779.
36. Overman, MJ,McDermott, R,Leach, JL(2017).Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.Lancet Oncol,18,1182.
37. Patel, MR,Ellerton, J,Infante, JR(2017).Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): Pooled results from two expansion cohorts of an open-label, phase 1 trial.Lancet Oncol
38. Postow, Michael A.,Sidlow, Robert(2018).Im mune-related adverse events associated with immune checkpoint blockade.N Engl J Med,378,158-168.
39. Powles, T,O’Donnell, PH,Massard, C(2017).Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.JAMA Oncol,3,e172411.
40. Reck, M,Rodriguez-Abreu, D,Robinson, AG(2016).Pembrolizumab versus chemotherapy for PD-L1 positive non-smallcell lung cancer.N Engl J Med,375,1823-1833.
41. Ribas, A,Puzanov, I,Dummer, R(2015).Pembrolizumab versus investigator-choice chemo-therapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial.Lancet Oncol,16,908.
42. Rittmeyer, A,Barlesi, F,Waterkamp, D(2017).Atezolizumab versus docetaxel in patients with previously treated nonsmall-cell lung cancer (OAK): A phase 3, openlabel, multicentre randomised controlled trial.Lancet,389,255-265.
43. Robert, C,Long, GV,Brady, B(2015).Nivolumab in previously untreated melanoma without BRAF mutation.N Engl J Med,372,320.
44. Robert, C,Schachter, J,Long, GV(2015).Pembrolizumab versus Ipilimumab in Advanced Melanoma.N Engl J Med,372,2521.
45. Robert, C,Thomas, L,Bondarenko, I(2011).Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.N Engl J Med,364,2517.
46. Rosenberg, JE,Hoffman-Censits, J,Powles, T(2016).Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial.Lancet,387,1909.
47. Saenger, YM,Wolchok, JD(2008).The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: Patient cases.Cancer Immun,8,1.
48. Schachter, J,Ribas, A,Long, GV(2017).Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).Lancet,390,1853.
49. Schiller, JH,Harrington, D,Belani, CP(2002).Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.N Engl J Med,346,92-98.
50. Sharma, P,Retz, M,Siefker-Radtke, A(2017).Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial.Lancet Oncol
51. Socinski, M,Creelan, B,Hom, L(2016).Check-Mate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinumbased doublet chemotherapy (PT-DC) as first-line therapy for stage IV/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC.Ann Oncol,27(suppl_6),LBA7_PR.
52. Topalian, SL,Hodi, FS,Brahmer, JR(2012).Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.N Engl J Med,366,2443-2454.
53. Tumeh, PC,Harview, CL,Yearley, JH(2014).PD-1 blockade induces responses by inhibiting adaptive immune resistance.Nature,515,568.
54. von der Maase, H,Hansen, SW,Roberts, JT(2000).Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study.J Clin Oncol,18,3068.
55. von der Maase, H,Sengelov, L,Roberts, JT(2005).Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.J Clin Oncol,23,4602.
56. Wainberg, Z.A.,Jalal, S.,Muro, K.(2017).LBA28_PR KEYNOTE-059 Update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer.Annals of Oncology,28(suppl_5)
57. Weber, JS,D’Angelo, SP,Minor, D(2015).Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial.Lancet Oncol,16,375.
58. Weber, JS,Hodi, FS,Wolchok, JD(2017).Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma.J Clin Oncol,35,785-792.
59. Wolchok, JD,Chiarion-Sileni, V,Gonzalez, R(2017).Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.N Engl J Med,377,1345.
60. Wolchok, JD,Hoos, A,O’Day, S(2009).Guidelines for the evaluation of immune therapy activity in solid tumors: Immunerelated response criteria.Clin Cancer Res,15,7412-7420.
61. Younes, A,Santoro, A,Shipp, M(2016).Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial.Lancet Oncol,17,1283.